Advertisement

Best Practice for Clinical Somatic Variant Interpretation and Reporting

  • Author Footnotes
    1 Contributed equally.
    Jeffrey Schubert
    Footnotes
    1 Contributed equally.
    Affiliations
    Division of Genomic Diagnostics, Department of Pathology & Laboratory Medicine, The Children’s Hospital of Philadelphia, 3615 Civic Center boulevard, 706 ARC, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Author Footnotes
    1 Contributed equally.
    Jinhua Wu
    Footnotes
    1 Contributed equally.
    Affiliations
    Division of Genomic Diagnostics, Department of Pathology & Laboratory Medicine, The Children’s Hospital of Philadelphia, 3615 Civic Center boulevard, 706 ARC, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Marilyn M. Li
    Affiliations
    Division of Genomic Diagnostics, Department of Pathology & Laboratory Medicine, The Children’s Hospital of Philadelphia, 3615 Civic Center boulevard, 706 ARC, Philadelphia, PA 19104, USA

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
    Search for articles by this author
  • Kajia Cao
    Correspondence
    Corresponding author.
    Affiliations
    Division of Genomic Diagnostics, Department of Pathology & Laboratory Medicine, The Children’s Hospital of Philadelphia, 3615 Civic Center boulevard, 706 ARC, Philadelphia, PA 19104, USA
    Search for articles by this author
  • Author Footnotes
    1 Contributed equally.
Published:August 22, 2022DOI:https://doi.org/10.1016/j.cll.2022.04.006

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Forrest S.J.
        • Geoerger B.
        • Janeway K.A.
        Precision medicine in pediatric oncology.
        Curr Opin Pediatr. 2018; 30: 17-24
        • Sicklick J.K.
        • Kato S.
        • Okamura R.
        • et al.
        Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
        Nat Med. 2019; 25: 744-750
        • Tsimberidou A.M.
        • Fountzilas E.
        • Nikanjam M.
        • et al.
        Review of precision cancer medicine: Evolution of the treatment paradigm.
        Cancer Treat Rev. 2020; 86: 102019
        • van Dijk E.L.
        • Auger H.
        • Jaszczyszyn Y.
        • et al.
        Ten years of next-generation sequencing technology.
        Trends Genet. 2014; 30: 418-426
        • Wong K.C.
        Big data challenges in genome informatics.
        Biophys Rev. 2019; 11: 51-54
        • ITP-CAoWG Consortium
        Pan-cancer analysis of whole genomes.
        Nature. 2020; 578: 82-93
        • Sabour L.
        • Sabour M.
        • Ghorbian S.
        Clinical applications of next-generation sequencing in cancer diagnosis.
        Pathol Oncol Res. 2017; 23: 225-234
        • Li M.M.
        • Datto M.
        • Duncavage E.J.
        • et al.
        Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular Pathology, American Society of clinical oncology, and College of American Pathologists.
        J Mol Diagn. 2017; 19: 4-23
        • Richards S.
        • Aziz N.
        • Bale S.
        • et al.
        Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular Pathology.
        Genet Med. 2015; 17: 405-424
        • Cottrell C.E.
        • Al-Kateb H.
        • Bredemeyer A.J.
        • et al.
        Validation of a next-generation sequencing assay for clinical molecular oncology.
        J Mol Diagn. 2014; 16: 89-105
        • Sukhai M.A.
        • Craddock K.J.
        • Thomas M.
        • et al.
        A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer.
        Genet Med. 2016; 18: 128-136
        • Van Allen E.M.
        • Wagle N.
        • Stojanov P.
        • et al.
        Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
        Nat Med. 2014; 20: 682-688
        • Krzyszczyk P.
        • Acevedo A.
        • Davidoff E.J.
        • et al.
        The growing role of precision and personalized medicine for cancer treatment.
        Technology (Singap World Sci). 2018; 6: 79-100
        • Louis D.N.
        • Perry A.
        • Reifenberger G.
        • et al.
        The 2016 World Health organization classification of tumors of the Central Nervous system: a summary.
        Acta Neuropathol. 2016; 131: 803-820
        • Zhong Y.
        • Xu F.
        • Wu J.
        • et al.
        Application of next generation sequencing in laboratory medicine.
        Ann Lab Med. 2021; 41: 25-43
        • Nie Q.
        • Hsiao M.C.
        • Chandok H.
        • et al.
        Molecular profiling of CNS tumors for the treatment and management of disease.
        J Clin Neurosci. 2020; 71: 311-315
        • Özdoğan M.
        • Papadopoulou E.
        • Tsoulos N.
        • et al.
        Comprehensive tumor molecular profile analysis in clinical practice.
        BMC Med Genomics. 2021; 14: 105
        • Surrey L.F.
        • MacFarland S.P.
        • Chang F.
        • et al.
        Clinical utility of custom-designed NGS panel testing in pediatric tumors.
        Genome Med. 2019; 11: 32
        • Gao P.
        • Zhang R.
        • Li Z.
        • et al.
        Challenges of providing concordant interpretation of somatic variants in non-small cell Lung cancer: a Multicenter study.
        J Cancer. 2019; 10: 1814-1824
        • Sirohi D.
        • Schmidt R.L.
        • Aisner D.L.
        • et al.
        Multi-institutional evaluation of Interrater Agreement of variant classification based on the 2017 association for molecular Pathology, American Society of clinical oncology, and College of American Pathologists standards and guidelines for the interpretation and reporting of sequence variants in cancer.
        J Mol Diagn. 2020; 22: 284-293
        • Parikh B.A.
        • Love-Gregory L.
        • Duncavage E.J.
        • et al.
        Identification of challenges and a framework for implementation of the AMP/ASCO/CAP classification guidelines for reporting somatic variants.
        Pract Lab Med. 2020; 21: e00170
        • Irwin M.S.
        • Naranjo A.
        • Zhang F.F.
        • et al.
        Revised neuroblastoma risk classification system: a Report from the Children's oncology group.
        J Clin Oncol. 2021; (JCO2100278)
        • Lindeman N.I.
        • Cagle P.T.
        • Aisner D.L.
        • et al.
        Updated molecular testing guideline for the selection of Lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International association for the study of Lung cancer, and the association for molecular Pathology.
        Arch Pathol Lab Med. 2018; 142: 321-346
        • Banck H.
        • Dugas M.
        • MÜller-Tidow C.
        • et al.
        Comparison of open-access databases for clinical variant interpretation in cancer: a Case study of MDS/AML.
        Cancer Genomics Proteomics. 2021; 18: 157-166
        • Wagner A.H.
        • Walsh B.
        • Mayfield G.
        • et al.
        A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer.
        Nat Genet. 2020; 52: 448-457
        • He M.M.
        • Li Q.
        • Yan M.
        • et al.
        Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants.
        Genome Med. 2019; 11: 53
        • Tamborero D.
        • Rubio-Perez C.
        • Deu-Pons J.
        • et al.
        Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.
        Genome Med. 2018; 10: 25
        • Cibulskis K.
        • Lawrence M.S.
        • Carter S.L.
        • et al.
        Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.
        Nat Biotechnol. 2013; 31: 213-219
        • Fang H.
        • Bergmann E.A.
        • Arora K.
        • et al.
        Indel variant analysis of short-read sequencing data with Scalpel.
        Nat Protoc. 2016; 11: 2529-2548
      1. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:12073907. 2012.

        • Koboldt D.C.
        • Zhang Q.
        • Larson D.E.
        • et al.
        VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.
        Genome Res. 2012; 22: 568-576
        • Ye K.
        • Schulz M.H.
        • Long Q.
        • et al.
        Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads.
        Bioinformatics. 2009; 25: 2865-2871
        • The I.
        • of Whole T.P.-C.A.
        • Consortium G.
        Pan-cancer analysis of whole genomes.
        Nature. 2020; 578: 82
        • Kroigard A.B.
        • Thomassen M.
        • Laenkholm A.V.
        • et al.
        Evaluation of nine somatic variant callers for detection of somatic mutations in exome and targeted Deep sequencing data.
        PLoS One. 2016; 11e0151664
        • Wu C.
        • Zhao X.
        • Welsh M.
        • et al.
        Using machine learning to identify true somatic variants from next-generation sequencing.
        Clin Chem. 2020; 66: 239-246
        • Futreal P.A.
        • Coin L.
        • Marshall M.
        • et al.
        A census of human cancer genes.
        Nat Rev Cancer. 2004; 4: 177-183
        • Sever R.
        • Brugge J.S.
        Signal transduction in cancer.
        Cold Spring Harb Perspect Med. 2015; 5
        • Sondka Z.
        • Bamford S.
        • Cole C.G.
        • et al.
        The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.
        Nat Rev Cancer. 2018; 18: 696-705
        • Agnarsson B.A.
        • Jonasson J.G.
        • Bjornsdottir I.B.
        • et al.
        Inherited BRCA2 mutation associated with high grade breast cancer.
        Breast Cancer Res Treat. 1998; 47: 121-127
        • Klein A.P.
        Genetic susceptibility to pancreatic cancer.
        Mol Carcinog. 2012; 51: 14-24
        • Goh A.M.
        • Coffill C.R.
        • Lane D.P.
        The role of mutant p53 in human cancer.
        J Pathol. 2011; 223: 116-126
        • Du Z.
        • Lovly C.M.
        Mechanisms of receptor tyrosine kinase activation in cancer.
        Mol Cancer. 2018; 17: 58
        • van Oijen M.G.
        • Slootweg P.J.
        Gain-of-function mutations in the tumor suppressor gene p53.
        Clin Cancer Res. 2000; 6: 2138-2145
        • Nakao M.
        • Yokota S.
        • Iwai T.
        • et al.
        Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
        Leukemia. 1996; 10: 1911-1918
        • Astolfi A.
        • Fiore M.
        • Melchionda F.
        • et al.
        BCOR involvement in cancer.
        Epigenomics. 2019; 11: 835-855
        • Gallant J.N.
        • Sheehan J.H.
        • Shaver T.M.
        • et al.
        EGFR kinase domain duplication (EGFR-KDD) is a Novel oncogenic driver in Lung cancer that is clinically responsive to Afatinib.
        Cancer Discov. 2015; 5: 1155-1163
        • Chen H.Y.
        • Brady D.C.
        • Villanueva J.
        Double Trouble: kinase domain duplication as a new path to drug resistance.
        Pigment Cell Melanoma Res. 2016; 29: 493-495
        • Jones D.T.
        • Hutter B.
        • Jager N.
        • et al.
        Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
        Nat Genet. 2013; 45: 927-932
        • Heist R.S.
        • Shim H.S.
        • Gingipally S.
        • et al.
        MET Exon 14 skipping in non-small cell Lung cancer.
        Oncologist. 2016; 21: 481-486
        • Dzieran J.
        • Rodriguez Garcia A.
        • Westermark U.K.
        • et al.
        MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.
        Proc Natl Acad Sci U S A. 2018; 115: E1229-E1238
        • Hecht J.L.
        • Aster J.C.
        Molecular biology of Burkitt's lymphoma.
        J Clin Oncol. 2000; 18: 3707-3721
        • Jain P.
        • Surrey L.F.
        • Straka J.
        • et al.
        BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers.
        Pediatr Blood Cancer. 2021; 68: e28933
        • Sutcliffe M.J.
        • Shuster J.J.
        • Sather H.N.
        • et al.
        High concordance from independent studies by the Children's cancer group (CCG) and pediatric oncology group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children's oncology group (COG) initiative.
        Leukemia. 2005; 19: 734-740
        • Cocco E.
        • Scaltriti M.
        • Drilon A.
        NTRK fusion-positive cancers and TRK inhibitor therapy.
        Nat Rev Clin Oncol. 2018; 15: 731-747
        • Harvey R.C.
        • Mullighan C.G.
        • Chen I.M.
        • et al.
        Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
        Blood. 2010; 115: 5312-5321
      2. Table of Pharmacogenomic biomarkers in drug labeling.
        (Available at:) (Accessed September, 2021)
        • Zhang J.W.
        • Wang J.Y.
        • Chen S.J.
        • et al.
        Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells.
        J Biosci. 2000; 25: 275-284
        • Locatelli F.
        • Niemeyer C.M.
        How I treat juvenile myelomonocytic leukemia.
        Blood. 2015; 125: 1083-1090
        • Taylor J.
        • Xiao W.
        • Abdel-Wahab O.
        Diagnosis and classification of hematologic malignancies on the basis of genetics.
        Blood. 2017; 130: 410-423